| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 21.03.2018 og
angivet som gældende fra 20.03.2018 (2389
dage). |
Ingen historik.
| Branche | | Fremstilling af farmaceutiske præparater (212000). |
| Sidst opdateret den 21.03.2018 og
angivet som gældende fra 20.03.2018 (2389
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 08.04.2020 og
angivet som gældende fra 08.04.2020 (1639
dage). |
| Historik | Start | Stop |
|---|
| false | 08.04.2020 | |
| true | 20.03.2018 | 07.04.2020 |
| Kontaktoplysninger | | INFO@DANCANN.COM. |
| Sidst opdateret den 23.08.2021 og
angivet som gældende fra 23.08.2021 (1137
dage). |
| Historik | Start | Stop |
|---|
| INFO@DANCANN.COM | 23.08.2021 | |
| JKR@DANCANN.COM | 30.04.2018 | 22.08.2021 |
| Telefonnummer | | 69160393. |
| Sidst opdateret den 23.08.2021 og
angivet som gældende fra 23.08.2021 (1137
dage). |
| Historik | Start | Stop |
|---|
| 69160393 | 23.08.2021 | |
| 29636920 | 30.04.2018 | 22.08.2021 |
| Navne | | DANCANN PHARMA A/S. |
| Sidst opdateret den 04.08.2020 og
angivet som gældende fra 06.07.2020 (1550
dage). |
| Historik | Start | Stop |
|---|
| DANCANN PHARMA A/S | 06.07.2020 | |
| DANCANN PHARMA ApS | 26.06.2020 | 05.07.2020 |
| DANCANN PHARMA IVS | 04.12.2019 | 25.06.2020 |
| DANCANN IVS | 20.03.2018 | 03.12.2019 |
| Binavne | | Danish Cannabinoids Pharmaceuticals A/S. |
| Sidst opdateret den 04.08.2020 og
angivet som gældende fra 06.07.2020 (1550
dage). |
| Historik | Start | Stop |
|---|
| Danish Cannabinoids Pharmaceuticals A/S | 06.07.2020 | |
| Danish Cannabis Pharmaceuticals A/S | 06.07.2020 | |
| Danish Cannabinoids Pharmaceuticals ApS | 26.06.2020 | 05.07.2020 |
| Danish Cannabis Pharmaceuticals ApS | 26.06.2020 | 05.07.2020 |
| Danish Cannabinoids Pharmaceuticals IVS | 04.12.2019 | 25.06.2020 |
| Danish Cannabis Pharmaceuticals IVS | 04.12.2019 | 25.06.2020 |
| Tegningsregel | | Selskabet tegnes af direktøren og bestyrelsesformanden i forening eller af den samlede bestyrelse. |
| Sidst opdateret den 08.04.2020 og
angivet som gældende fra 08.04.2020 (1639
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | direktøren + formanden |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af direktøren og bestyrelsesformanden i forening eller af den samlede bestyrelse | 08.04.2020 | |
| Selskabet tegnes af en direktør alene | 20.03.2018 | 07.04.2020 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards onAuditing (ISAs) and additional requirements applicable in Denmark. Ourresponsibilities under those standards and requirements are further de-scribed in the “Auditor’s responsibilities for the audit of the consolidatedfinancial statements and the parent financial statements” section of thisauditor’s report. We are independent of the Group in accordance withthe International Ethics Standards Board for Accountants’ InternationalCode of Ethics for Professional Accountants (IESBA Code) and the ad-ditional ethical requirements applicable in Denmark, and we have fulfilledour other ethical responsibilities in accordance with these requirementsand the IESBA Code. We believe that the audit evidence we have ob-tained is sufficient and appropriate to provide a basis for our opinion. Material uncertainty related to going concernWe draw attention to note 1 in the financial statements which highlightthat sufficient funding for the remaining part of the financial year 2024 isnot secured at the time of approval of the financial statements. Manage-ment have described the plans for obtaining sufficient financing and isof the opinion that it is possible to accomplish these successfully. Ourconclusion is not qualified in this respect, but emphasis is made due tothe uncertainty related this matter.
Konklusion (revision):OpinionWe have audited the consolidated financial statements and the par-ent financial statements of Dancann Pharma A/S for the financial year01. 01. 2023-31. 12. 2023, which comprise the income statement, balancesheet, statement of changes in equity and notes, including a summary ofsignificant accounting policies, for the Group as well as the Parent, andthe consolidated cash flow statement. The consolidated financial state-ments and the parent financial statements are prepared in accordancewith the Danish Financial Statements Act. In our opinion, the consolidated financial statements and the parentfinancial statements give a true and fair view of the Group’s and theParent’s financial position at 31. 12. 2023 and of the results of their opera-tions and the consolidated cash flows for the financial year 01. 01. 2023-31. 12. 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the management commentaryManagement is responsible for the management commentaryOur opinion on the consolidated financial statements and the parentfinancial statements døs not cover the management commentary, andwe do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated financial statementsand the parent financial statements, our responsibility is to read themanagement commentary and, in doing so, consider whether themanagement commentary is materially inconsistent with the consol-idated financial statements and the parent financial statements or ourknowledge obtained in the audit or otherwise appears to be materiallymisstated. Moreover, it is our responsibility to consider whether the managementcommentary provides the information required under the Danish Finan-cial Statements Act. Based on the work we have performed, we conclude that the man-agement commentary is in accordance with the consolidated financialstatements and the parent financial statements and has been preparedin accordance with the requirements of the Danish Financial StatementsAct. We did not identify any material misstatement of the managementcommentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Hjemmeside | | https://dancann.com. |
| Sidst opdateret den 30.04.2018 og
angivet som gældende fra 30.04.2018 (2348
dage). |
Ingen historik.
LoginOpret gratis brugere-conomic integration